Telormedix logo

Telormedix is a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases. 

OUR MISSION - to evaluate and establish the role of innate immunity in fighting cancer and infectious diseases.

The Company’s lead product, Vesimune (TMX-101), has currently completed a Phase IIa clinical trial for the localised treatment of bladder cancer, a disease of unmet medical need. Telormedix has also developed a portfolio of new generation of potent and highly selective TLR7 agonists for systemic and topical administration in different cancer indications and for use as a vaccine adjuvant. Founded in October 2007, Telormedix is located in Switzerland and is led by a highly experienced management team and backed by a consortium of leading global investors.